Advanced search×

Superoxide anion scavenging properties of fluvastatin and its metabolites.

Chem Pharm Bull (Tokyo) 47(10):1477-80 (1999) PMID 10553644

We investigated the in vitro superoxide anion scavenging activities of fluvastatin and its metabolites. Fluvastatin showed dose-dependent superoxide anion scavenging activity in the NADH/phenazine methosulphate (PMS)/nitroblue tetrazolium (NBT) system, and the effect was as potent as the reference antioxidant, trolox, which is a water-soluble alpha-tocopherol derivative. The superoxide anion scavenging activities of the major metabolites of fluvastatin (M2, M3, M4, M7) were also determined in this system. All of these metabolites showed the activity. In particular, M2 and M3, which possess a phenolic hydroxyl group at the 5 or 6-position of the indole moiety, respectively, showed 3 times stronger activities than that of fluvastatin. Further, we also determined the effects of fluvastatin, M2 and M3 on phorbol myristate acetate (PMA)-induced superoxide anion generation in human peripheral blood polymorphonuclear leukocytes (PMN). The compounds tested also showed a depressing effect on the amount of superoxide anion in this system. We suggest that fluvastatin and its metabolites have the potential to protect cells or lipids from oxidative modification mediated by superoxide anion.

Version: za2963e q8za8 q8zba q8zc5 q8zdd q8ze0 q8zf8 q8zgb

Similar articles you may find interesting…

  1. A simple, iron-catalyzed, pyridine-assisted hydrogen peroxide epoxidation system.

    Chem Pharm Bull (Tokyo) 59(6):799-801 (2011) PMID 21628924

    A simple and inexpensive system comprised of H(2)O(2)-pyridine-FeCl(3)ยท6H(2)O for the catalysis of olefin epoxidation was established. Intriguingly, the reactivity of this system greatly depends on the amounts of pyridine. Various substrates, including aromatic and aliphatic olefins...
  2. Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate (YM872).

    Chem Pharm Bull (Tokyo) 52(11):1322-5 (2004) PMID 15516754